(Q48623725)

English

Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer

scientific article published on 25 July 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

adaptive radiation therapy

0 references

author name string

Michael Pinkawa

1

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

Marc D Piroth

2

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

Richard Holy

3

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

Victoria Djukic

4

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

Jens Klotz

5

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

Barbara Krenkel

6

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

Michael J Eble

7

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

publication date

25 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

Strahlentherapie und Onkologie

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

187

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

8

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

479-484

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding

1 reference

https://api.crossref.org/works/10.1007%2FS00066-011-2249-Z

21 January 2018

Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00066-011-2249-Z

21 January 2018

Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00066-011-2249-Z

21 January 2018

Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison

1 reference

https://api.crossref.org/works/10.1007%2FS00066-011-2249-Z

21 January 2018

Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00066-011-2249-Z

21 January 2018

Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy.

1 reference

https://api.crossref.org/works/10.1007%2FS00066-011-2249-Z

21 January 2018

Consequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study

1 reference

https://api.crossref.org/works/10.1007%2FS00066-011-2249-Z

21 January 2018

Intensity-Modulated Radiotherapy for Prostate Cancer Implementing Molecular Imaging with 18F-Choline PET-CT to Define a Simultaneous Integrated Boost

1 reference

https://api.crossref.org/works/10.1007%2FS00066-011-2249-Z

21 January 2018

Impact of the target volume (prostate alone vs. prostate with seminal vesicles) and fraction dose (1.8 Gy vs. 2.0 Gy) on quality of life changes after external-beam radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00066-011-2249-Z

21 January 2018

Image-guided radiotherapy for prostate cancer. Implementation of ultrasound-based prostate localization for the analysis of inter- and intrafraction organ motion

1 reference

https://api.crossref.org/works/10.1007%2FS00066-011-2249-Z

21 January 2018

Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial

1 reference

https://api.crossref.org/works/10.1007%2FS00066-011-2249-Z

21 January 2018

Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS00066-011-2249-Z

21 January 2018

Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00066-011-2249-Z

21 January 2018

ICRU reference dose in an era of intensity-modulated radiation therapy clinical trials: correlation with planning target volume mean dose and suitability for intensity-modulated radiation therapy dose prescription

1 reference

https://api.crossref.org/works/10.1007%2FS00066-011-2249-Z

21 January 2018

Quality of Life After Whole Pelvic Versus Prostate-Only External Beam Radiotherapy for Prostate Cancer: A Matched-Pair Comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/21789739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21789739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of anorectal dose-volume histograms and impaired fecal continence after 3D conformal radiotherapy for carcinoma of the prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/21789739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postoperative radiotherapy for prostate cancer : evaluation of target motion and treatment techniques (intensity-modulated versus conformal radiotherapy)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21789739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21789739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21789739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of Treatment Volumes and Techniques in Prostate Cancer Radiation Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21789739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

1 reference

https://pubmed.ncbi.nlm.nih.gov/21789739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21789739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V

1 reference

https://pubmed.ncbi.nlm.nih.gov/21789739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced rectal toxicity with ultrasound-based image guided radiotherapy using BAT (B-mode acquisition and targeting system) for prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21789739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fractionation and late rectal toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/21789739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/21789739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21789739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00066-011-2249-Z

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/21789739

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48623725&oldid=2209650085"